Navigation Links
SanBio Receives FDA Clearance to Initiate Cell Therapy Clinical Studies for Stroke Recovery

MOUNTAIN VIEW, Calif., June 16 /PRNewswire/ -- SanBio Inc. ( announced today that the United States Food and Drug Administration (FDA) has approved the clinical testing of their SB623 regenerative medicine product in patients suffering from disability caused by cerebral stroke. SB623 is derived from bone marrow stromal cells (MSCs) isolated from healthy adult donors.

This Phase 1/2a clinical trial will test the safety of SB623 when implanted in the damaged regions of the brains of stable stroke patients. "We are pleased and proud to be given the opportunity to move this therapeutic approach forward. This is the only clinical trial currently open in the United States testing the regenerative potential of cell therapy in the brain," said Kieta Mori, co-CEO of SanBio. "This cell product has the potential to change the lives of patients afflicted by stroke injury," said Dr. Douglas Kondziolka, the Peter J. Jannetta Professor of Neurological Surgery in the Department of Neurological Surgery, Director, Center for Brain Function and Behavior at the University of Pittsburgh School of Medicine and a Principal Investigator in the SB623 clinical trial. According to the American Heart Association, stroke is the third leading cause of death in the United States and the leading cause of serious long-term disability. "Cell therapy has great potential in many degenerative diseases of the central nervous system. SB623's entry into human clinical testing marks an important step forward for the field," said Dr. Gary Steinberg, the Lacroute-Hearst Professor, Chairman of the Department of Neurosurgery, and Director of the Stanford Institute for Neuro-Innnovation and Translational Neurosciences at the Stanford University School of Medicine. Dr. Steinberg is also a Principal Investigator in the SB623 clinical trial.

About SB623: SB623 is a proprietary population of regenerative cells derived from genetically engineered bone marrow stromal cells (MSCs) obtained from healthy adult donors. SB623 is implanted directly adjacent to the area damaged by stroke and functions by producing proteins that aid the healing process. The development of SB623 is based on earlier research by Professor Mari Dezawa of Tohoku University.

About SanBio: SanBio is a privately held San Francisco Bay Area biotechnology company focused on the discovery and development of regenerative cell therapy products.

SOURCE SanBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
(Date:11/30/2015)... Cumberland Pharmaceuticals (CPIX), today announced that A.J. Kazimi ... December 3, 2015. TIME: 3:15p.m. ET LINK: ... --> DATE: Thursday, December ... --> --> This will ... to ask the company questions in real-time - both in ...
(Date:11/30/2015)... 2015 NHS Supply Chain has placed ... from Varian Medical Systems (NYSE: VAR ) ... older machines and institute modern radiotherapy and radiosurgery ... The order, placed in September, also includes ten ... RapidArc® and Eclipse™ software systems.    ...
(Date:11/30/2015)... Texas , Nov. 30, 2015  Hanger, Inc. ... amendment and restatement of the terms of its previously ... Solicitation") relating to its $200,000,000 aggregate principal amount 7⅛% ... other things, (i) the consent fees payable pursuant to ... on the Notes and (iii) the expiration date of ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... The directory is specialized and only includes chiropractic clinics in the US. , ... and trustworthy alternative health practitioner when back pain sets in. When people are ...
(Date:11/30/2015)... Flint, Michigan (PRWEB) , ... November 30, 2015 ... ... a safe and fun atmosphere for Halloween festivities, the Word of Life Christian ... classic children’s board game, and featuring a giant 1.25 ton pile of candy ...
(Date:11/30/2015)... ... November 30, 2015 , ... During ... fundraising campaign to raise funds for its research, education, support, and advocacy efforts. ... organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes by ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Catalyst continuing education course in Dallas, TX, on January 29 and 30, 2016. ... to improve the functions of their practices, to learn how to better succeed ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... comparison chart and ingredient list of its hemorrhoid ointment to its website. , ... pain relief for people suffering from hemorrhoids. Adding the comparison chart and ingredient ...
Breaking Medicine News(10 mins):